Nannocystin ax, an eEF1A inhibitor, induces G1 cell cycle arrest and caspase-independent apoptosis through cyclin D1 downregulation in colon cancer in vivo

• DOI: 10.1016/j.phrs.2021.105870
• Publication Date: 2021-09-07T01:18:53Z
• Authors: Ying Hou; Rong Liu; Mengwei Xia; Chong Sun; Bingling Zhong; Jie Yu; Nana Ai; Jin-Jian Lu; Wei Ge; Bo Liu; Xiuping Chen
• Keywords: Membrane Potential, Mitochondrial; 0301 basic medicine; 0303 health sciences; Down-Regulation; Antineoplastic Agents; Apoptosis; HCT116 Cells; G1 Phase Cell Cycle Checkpoints; 3. Good health; 03 medical and health sciences; Peptide Elongation Factor 1; Caspases; Depsipeptides; Colonic Neoplasms; Animals; Humans; Cyclin D1; HT29 Cells; Zebrafish

Colorectal cancer (CRC) is one of the most common causes of cancer-related death worldwide. Nannocystin ax (NAN), a 21-membered cyclodepsipeptide initially isolated from myxobacteria of the Nannocystis genus, was found to target the eukaryotic elongation factor 1A (eEF1A). The current study was designed to evaluate the anticancer effect and underlying mechanisms of NAN with in vitro and in vivo models. Results showed that NAN induced G1 phase cell cycle arrest and caspase-independent apoptosis in HCT116 and HT29 human CRC cells. NAN significantly downregulated cyclin D1 level in a short time, but NAN did not affect the transcription level and ubiquitin-dependent degradation of cyclin D1. Furthermore, NAN treatment directly targeted eEF1A and partially decreased the synthesis of new proteins, contributing to the downregulation of cyclin D1. Besides, NAN significantly suppressed tumor growth in the zebrafish xenograft model. In conclusion, NAN triggered G1 phase cell cycle arrest through cyclin D1 downregulation and eEF1A-targeted translation inhibition and promoted caspase-independent apoptosis in CRC cells.